GuidelineJournal of neuro-oncology2014
The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Guideline in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013.Journal of neuro-oncology · 2014Pooled it
- Phase II study of PX-866 in recurrent glioblastoma.Neuro-oncology · 2015Trial
- Efficacy of Anlotinib in Treating Progressive Glioblastoma: Insights From a Single-Center Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Article
- High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients.Frontiers in immunology · 2024Article
- NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.Cancer treatment and research communications · 2021Article
- Statistical multiscale mapping of IDH1, MGMT, and microvascular proliferation in human brain tumors from multiparametric MR and spatially-registered core biopsy.Scientific reports · 2019Article
- Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.Medicine · 2019Review
- Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?Neuro-oncology · 2019Review
- Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma.Life science alliance · 2018Article
- Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry.CNS oncology · 2018Observational
- Immunotherapies for malignant glioma.Oncogene · 2018Review
- Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials.Cancer management and research · 2018Article
- Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.Journal of cellular biochemistry · 2017Review
- Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.Journal of neuro-oncology · 2016Article
- Controlled Drug Release and Chemotherapy Response in a Novel Acoustofluidic 3D Tumor Platform.Small (Weinheim an der Bergstrasse, Germany) · 2016Article
- Increased diffusion in the normal appearing white matter of brain tumor patients: is this just tumor infiltration?Journal of neuro-oncology · 2016Article
- Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.Journal of neuro-oncology · 2015Article
- Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.The British journal of radiology · 2015Review
- Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.Neuro-oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
questionWhat is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma? TARGETED POPULATION: This recommendation applies to adult patients with progressive glioblastoma RECOMMENDATIONS: Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months. Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.